Emricasan

• CAT Number: I002870
• CAS Number: 254750-02-2
• Molecular Formula: C26H27F4N3O7
• Molecular Weight: 569.5
• Purity: ≥95%
• Target: Caspase
• Solubility: DMSO: ≥ 42 mg/mL
• Storage: Store at -20°C
• IC50: 10 mg/kg was required to prevent liver injury [1]
• InChI: InChI=1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1
• InChIKey: SCVHJVCATBPIHN-SJCJKPOMSA-N
• SMILES: CC(C)(C)C1=C(NC(C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(COC2=C(F)C(F)=CC(F)=C2F)=O)=O)=O)=O)C=CC=C1

Emricasan (CAT: I002870), also known as IDN-6556, PF 03491390, PF-03491390, is a potent, irreversible inhibitor of pan-caspase. emricasan is also an inhibitor of Zika virus infection. emricasan has neuroprotective activity against hNPCs but does not inhibit ZIKV replication.

Reference

1:The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Brumatti G, Ma C, Lalaoui N, Nguyen NY, Navarro M, Tanzer MC, Richmond J, Ghisi M, Salmon JM, Silke N, Pomilio G, Glaser SP, de Valle E, Gugasyan R, Gurthridge MA, Condon SM, Johnstone RW, Lock R, Salvesen G, Wei A, Vaux DL, Ekert PG, Silke J.Sci Transl Med. 2016 May 18;8(339):339ra69. doi: 10.1126/scitranslmed.aad3099. PMID: 27194727 2:Carcinogenicity assessment of the pan-caspase inhibitor, emricasan, in Tg.rasH2 mice. Elbekai RH, Paranjpe MG, Contreras PC, Spada A.Regul Toxicol Pharmacol. 2015 Jul;72(2):169-78. doi: 10.1016/j.yrtph.2015.04.007. Epub 2015 Apr 17. PMID: 25896096 3:The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, Carreras MC, Poderoso JJ, Gores GJ.Liver Int. 2015 Mar;35(3):953-66. doi: 10.1111/liv.12570. Epub 2014 Jun 6. PMID: 24750664